Nuclera

Nuclera makes eProtein Discovery, an automated multiplex protein screening system that runs parallel cell-free expression and binding assays on digital microfluidic cartridges to identify soluble, high-yield protein constructs. The company also sells an antibody screening service that tests 96 antibodies in parallel and runs single-cycle SPR on selected hits, with delivery from 14 business days.

Its customers are protein scientists in research and drug discovery, including biopharma companies and contract research organisations. The company sells the instrument, cartridges, reagents and software, and offers expression and purification and antibody services as paid work.

Nuclera was founded in 2013 at the University of Cambridge and its global headquarters is in Impington, Cambridge, UK, opened in 2023. It has a US facility in Billerica, Massachusetts. The website lists a Series C round of $75 million in 2024 and openings for senior software engineers in instrument and cloud roles and a senior reagent production and test technician in Cambridge.

Product: eProtein Discovery automated multiplex protein screening system with cartridges, reagents and software, plus antibody screening services